{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:31:28Z","timestamp":1786480288199,"version":"build-2736575974"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK 56942"],"award-info":[{"award-number":["DK 56942"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2022,7,28]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Selonsertib (SEL), a selective apoptosis signal-regulating kinase 1 inhibitor, targets an oxidative stress pathway in CKD.<\/jats:p>\n <\/jats:list-item>\n \n SEL plus enalapril reduces glomerulosclerosis, attenuates kidney function decline, and reduces podocyte loss more than either agent alone.<\/jats:p>\n <\/jats:list-item>\n \n SEL has a nonhemodynamic mechanism and has additional effects on apoptosis and fibrosis in the kidney when combined with standard of care.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Despite widespread use of renin-aldosterone-angiotensin system inhibitors and the benefits of lowering glomerular pressure in patients with CKD, there remains a major unmet need for therapies targeting underlying causes of CKD progression. Apoptosis signal-regulating kinase 1 (ASK1) promotes apoptosis and glomerulosclerosis, and is implicated in the progression of diabetic kidney disease (DKD), a major cause of CKD. Selonsertib is a selective ASK1 inhibitor currently in clinical development for the treatment of DKD. We examined the added benefits of selonsertib on existing glomerulosclerosis and related molecular pathways in the nondiabetic 5\/6 nephrectomy (5\/6 Nx) rat model in combination with the angiotensin-converting enzyme inhibitor (ACEI) enalapril.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Male Sprague Dawley rats underwent 5\/6 Nx with kidney biopsy 8 weeks later for assessment of glomerulosclerosis, and were randomized to four treatment groups with equal glomerulosclerosis: selonsertib, enalapril, combination (selonsertib plus enalapril), and untreated controls. Serum creatinine, systolic BP (SBP), and urinary albumin were measured at intervals. Animals were euthanized at week 12 for histologic, biochemical, and molecular analyses.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n All rats developed hypertension, albuminuria, and glomerulosclerosis by week 8. Kidney function further declined, and glomerulosclerosis and albuminuria progressively increased in controls from week 8 to 12. Enalapril treatment alone from week 8 to 12 reduced SBP versus controls, decreased albuminuria, and resulted in numerically lower glomerulosclerosis. Selonsertib alone had no effect on SBP but preserved kidney function. Combined treatment significantly reduced glomerulosclerosis, with more regression than either monotherapy. Enalapril treatment resulted in fewer interstitial macrophages, whereas selonsertib treatment reduced apoptosis and podocyte loss. RNA-seq revealed that combined treatment influenced pathways related to extracellular matrix and wound healing.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Selonsertib targets a novel, nonhemodynamic pathway in CKD. Our data suggest that ASK1 inhibition, when combined with ACEI, has additive effects to reduce progression of glomerulosclerosis, attenuate kidney function decline, and reduce podocyte loss.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0001032022","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T16:15:12Z","timestamp":1649693712000},"page":"1169-1182","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Selonsertib Enhances Kidney Protection Beyond Standard of Care in a Hypertensive, Secondary Glomerulosclerosis CKD Model"],"prefix":"10.34067","volume":"3","clinical-trial-number":[{"clinical-trial-number":"nct02177786","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04026165","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Shawn S.","family":"Badal","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareq","family":"Al Tuhaifi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Fen","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee"},{"name":"Fourth Hospital, Wuxi, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lopez","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig T.","family":"Plato","sequence":"additional","affiliation":[{"name":"PlatoBiopharma, Inc., Westminster, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Joly","sequence":"additional","affiliation":[{"name":"PlatoBiopharma, Inc., Westminster, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Breckenridge","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4265-7492","authenticated-orcid":false,"given":"Hai-Chun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Liles","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-8527","authenticated-orcid":false,"given":"Agnes B.","family":"Fogo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"B1-20250825","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ddmod.2010.08.002","article-title":"Models of chronic kidney disease","volume":"7","author":"Yang","year":"2010","journal-title":"Drug Discov Today Dis Models"},{"key":"B2-20250825","doi-asserted-by":"crossref","first-page":"F683","DOI":"10.1152\/ajprenal.00503.2009","article-title":"Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis","volume":"298","author":"Naito","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"B3-20250825","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1681\/ASN.2004060492","article-title":"Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1","volume":"16","author":"Ma","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B4-20250825","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/j.ackd.2014.04.001","article-title":"Mechanisms of disease reversal in focal and segmental glomerulosclerosis","volume":"21","author":"Yang","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"B5-20250825","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/embo-reports\/kve046","article-title":"ASK1 is required for sustained activations of JNK\/p38 MAP kinases and apoptosis","volume":"2","author":"Tobiume","year":"2001","journal-title":"EMBO Rep"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fphys.2017.00829","article-title":"The JNK signaling pathway in renal fibrosis","volume":"8","author":"Grynberg","year":"2017","journal-title":"Front Physiol"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41580-020-00322-w","article-title":"Diversity and versatility of p38 kinase signalling in health and disease","volume":"22","author":"Canovas","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B8-20250825","first-page":"1","article-title":"Pathophysiological roles of ASK1-MAP kinase signaling pathways","volume":"40","author":"Nagai","year":"2007","journal-title":"J Biochem Mol Biol"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00125-004-1437-0","article-title":"Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy","volume":"47","author":"Adhikary","year":"2004","journal-title":"Diabetologia"},{"key":"B10-20250825","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/j.ajkd.2004.08.039","article-title":"Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy","volume":"45","author":"Sakai","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B11-20250825","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1172\/JCI99768","article-title":"ASK1 contributes to fibrosis and dysfunction in models of kidney disease","volume":"128","author":"Liles","year":"2018","journal-title":"J Clin Invest"},{"key":"B12-20250825","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/ndt\/gfaa198","article-title":"Inhibition of apoptosis signal-regulating kinase 1 mitigates the pathogenesis of human immunodeficiency virus-associated nephropathy","volume":"36","author":"Chen","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B13-20250825","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1111\/jcmm.13705","article-title":"ASK1 inhibitor treatment suppresses p38\/JNK signalling with reduced kidney inflammation and fibrosis in rat crescentic glomerulonephritis","volume":"22","author":"Amos","year":"2018","journal-title":"J Cell Mol Med"},{"key":"B14-20250825","doi-asserted-by":"crossref","first-page":"F1263","DOI":"10.1152\/ajprenal.00211.2014","article-title":"ASK1\/p38 signaling in renal tubular epithelial cells promotes renal fibrosis in the mouse obstructed kidney","volume":"307","author":"Ma","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"B15-20250825","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1681\/ASN.2018121231","article-title":"Effects of selonsertib in patients with diabetic kidney disease","volume":"30","author":"Chertow","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B16-20250825","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1517\/14728222.2014.896903","article-title":"Apoptosis signal-regulating kinase 1 as a therapeutic target","volume":"18","author":"Kawarazaki","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"B17-20250825","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ndt\/gfg584","article-title":"Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats","volume":"19","author":"Luippold","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"B18-20250825","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ddmod.2014.06.003","article-title":"Animal models of regression\/progression of kidney disease","volume":"11","author":"Lim","year":"2014","journal-title":"Drug Discov Today Dis Models"},{"key":"B19-20250825","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/ki.2013.57","article-title":"Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes","volume":"83","author":"Bhensdadia","year":"2013","journal-title":"Kidney Int"},{"key":"B20-20250825","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.2337\/db13-0256","article-title":"Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"62","author":"Orchard","year":"2013","journal-title":"Diabetes"},{"key":"B21-20250825","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1046\/j.1523-1755.2000.00301.x","article-title":"Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis","volume":"58","author":"Gupta","year":"2000","journal-title":"Kidney Int"},{"key":"B22-20250825","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.34067\/KID.0001172021","article-title":"eGFR decline after SGLT2 inhibitor initiation: the tortoise and the hare reimagined","volume":"2","author":"Meraz-Mu\u00f1oz","year":"2021","journal-title":"Kidney360"},{"key":"B23-20250825","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2021070948","article-title":"Acute treatment effects on GFR in randomized clinical trials of kidney disease progression","volume":"33","author":"Neuen","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B24-20250825","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/0192623320937012","article-title":"Kidney transporters and drug-induced injury in drug development","volume":"48","author":"Radi","year":"2020","journal-title":"Toxicol Pathol"},{"key":"B25-20250825","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/HYPERTENSIONAHA.107.092049","article-title":"Apoptosis signal-regulating kinase-1 is involved in vascular endothelial and cardiac remodeling caused by nitric oxide deficiency","volume":"50","author":"Yamashita","year":"2007","journal-title":"Hypertension"},{"key":"B26-20250825","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"B27-20250825","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbior.2012.09.006","article-title":"Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling","volume":"53","author":"Shiizaki","year":"2013","journal-title":"Adv Biol Regul"},{"key":"B28-20250825","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri3495","article-title":"Mitogen-activated protein kinases in innate immunity","volume":"13","author":"Arthur","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B29-20250825","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2337\/db15-0384","article-title":"ASK1 inhibitor halts progression of diabetic nephropathy in Nos3-deficient mice","volume":"64","author":"Tesch","year":"2015","journal-title":"Diabetes"},{"key":"B30-20250825","doi-asserted-by":"crossref","first-page":"15883","DOI":"10.1073\/pnas.2136717100","article-title":"Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling","volume":"100","author":"Yamaguchi","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"B31-20250825","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev.pharmtox.48.113006.094606","article-title":"Apoptosis signal-regulating kinase 1 in stress and immune response","volume":"48","author":"Takeda","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B32-20250825","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1038\/s41598-018-23407-1","article-title":"Genetic markers for urine haptoglobin is associated with decline in renal function in type 2 diabetes in East Asians","volume":"8","author":"Gurung","year":"2018","journal-title":"Sci Rep"},{"key":"B33-20250825","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1681\/ASN.2019121285","article-title":"Urinary soluble CD163: A novel noninvasive biomarker of activity for lupus nephritis","volume":"31","author":"Mejia-Vilet","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B34-20250825","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1681\/ASN.2020101442","article-title":"Identification of an altered matrix signature in kidney aging and disease","volume":"32","author":"Randles","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B35-20250825","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41586-020-2941-1","article-title":"Decoding myofibroblast origins in human kidney fibrosis","volume":"589","author":"Kuppe","year":"2021","journal-title":"Nature"},{"key":"B36-20250825","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.2174\/0929867322666150625095407","article-title":"Insights into the mechanisms involved in the expression and regulation of extracellular matrix proteins in diabetic nephropathy","volume":"22","author":"Hu","year":"2015","journal-title":"Curr Med Chem"},{"key":"B37-20250825","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.2215\/CJN.01360217","article-title":"Urinary fibrinogen as a predictor of progression of CKD","volume":"12","author":"Wang","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B38-20250825","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/ki.2008.519","article-title":"Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4","volume":"74","author":"Goicoechea","year":"2008","journal-title":"Kidney Int Suppl"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0001032022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:01:33Z","timestamp":1786478493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0001032022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0001032022","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"assertion":[{"value":"2022-02-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}